<Record>
<Term>Yttrium Y 90 DOTA Monoclonal Antibody HuAFP31</Term>
<SemanticType>Pharmacologic Substance</SemanticType>
<ParentTerm>Radioimmunoconjugate</ParentTerm>
<ClassificationPath>Chemicals_and_Drugs_Kind/Drug, Food, Chemical or Biomedical Material/Pharmacologic Substance/Radiopharmaceutical Compound/Radioimmunoconjugate/Yttrium Y 90 DOTA Monoclonal Antibody HuAFP31</ClassificationPath>
<BroaderTerm>Radioimmunoconjugate</BroaderTerm>
<BroaderTerm>Radiopharmaceutical Compound</BroaderTerm>
<BroaderTerm>Chemicals_and_Drugs_Kind</BroaderTerm>
<BroaderTerm>Pharmacologic Substance</BroaderTerm>
<BroaderTerm>Yttrium Y 90 DOTA Monoclonal Antibody HuAFP31</BroaderTerm>
<BroaderTerm>Drug, Food, Chemical or Biomedical Material</BroaderTerm>
<Synonym>Yttrium Y 90 DOTA Monoclonal Antibody HuAFP31</Synonym>
<Description>A radioimmunoconjugate comprised of the monoclonal antibody HuAFP31, directed against alpha fetoprotein, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 DOTA monoclonal antibody HuAFP31 binds to tumor cells expressing alpha fetoprotein, selectively delivering a cytotoxic dose of beta radiation. (NCI05)</Description>
<Source>NCI Thesaurus</Source>
</Record>
